NASDAQ:RIGL Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis $45.35 -1.89 (-4.00%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$45.54 +0.19 (+0.42%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Rigel Pharmaceuticals Stock (NASDAQ:RIGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rigel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$44.96▼$47.5350-Day Range$36.74▼$49.4252-Week Range$24.95▼$52.24Volume335,806 shsAverage Volume265,111 shsMarket Capitalization$839.07 millionP/E Ratio2.78Dividend YieldN/APrice Target$59.00Consensus RatingModerate Buy Company Overview Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for immune and hematologic disorders. The company was founded in 1996 and is headquartered in South San Francisco, California. Its research programs have historically centered on signaling pathways involved in inflammation, autoimmune disease and cancer. Rigel’s principal commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Tavalisse is also marketed in certain international markets under the name Tavlesse, with regional commercialization supported by licensing and collaboration arrangements. The company has also expanded its oncology portfolio through rights to Rezlidhia (olutasidenib), an oral targeted therapy approved in the United States for adults with relapsed or refractory acute myeloid leukemia featuring a susceptible IDH1 mutation. Rigel continues to pursue additional product opportunities in hematology, oncology and immune-mediated diseases. Raul Rodriguez serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Rigel Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreRIGL MarketRank™: Rigel Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 28th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingRigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialRigel Pharmaceuticals has a consensus price target of $59.00, representing about 30.1% upside from its current price of $45.35.Amount of Analyst CoverageRigel Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rigel Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth44.97% Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to grow by 44.97% in the coming year, from $2.98 to $4.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is 2.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is 2.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.30.Price to Book Value per Share RatioRigel Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rigel Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.21% of the float of Rigel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRigel Pharmaceuticals has a short interest ratio ("days to cover") of 9.11.Change versus previous monthShort interest in Rigel Pharmaceuticals has recently decreased by 0.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentRigel Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat Follows5 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $87,500.00 in company stock.Percentage Held by Insiders10.47% of the stock of Rigel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rigel Pharmaceuticals' insider trading history. Receive RIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RIGL Stock News HeadlinesRigel Pharmaceuticals (NASDAQ:RIGL) and Aclaris Therapeutics (NASDAQ:ACRS) Critical ContrastSeptember 11, 2026 | americanbankingnews.comRigel to Participate in Upcoming September Investor ConferencesSeptember 2, 2026 | prnewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Rigel PharmaceuticalsAugust 17, 2026 | money.usnews.comRigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast CancerAugust 13, 2026 | prnewswire.comRigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst AheadAugust 5, 2026 | seekingalpha.comRigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)August 5, 2026 | seekingalpha.comRigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 4, 2026 | seekingalpha.comSee More Headlines RIGL Stock Analysis - Frequently Asked Questions How have RIGL shares performed this year? Rigel Pharmaceuticals' stock was trading at $42.83 at the start of the year. Since then, RIGL stock has increased by 5.9% and is now trading at $45.35. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its earnings results on Tuesday, August, 4th. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.79. The biotechnology company had revenue of $78.70 million for the quarter, compared to analyst estimates of $55.28 million. Rigel Pharmaceuticals had a net margin of 116.30% and a trailing twelve-month return on equity of 22.95%. Read the conference call transcript. When did Rigel Pharmaceuticals' stock split? Shares of Rigel Pharmaceuticals reverse split on the morning of Thursday, June 27th 2024.The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' top institutional shareholders include BlackRock Inc. (10.49%), Bank of America Corp DE (0.67%), Globeflex Capital L P (0.61%) and Bank of New York Mellon Corp (0.58%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno, David A Santos, Walter H Moos and Kamil Ali-Jackson. View institutional ownership trends. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings8/04/2026Today9/15/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RIGL's financial health is in the Green zone, according to TradeSmith. RIGL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RIGL CIK1034842 Webwww.rigel.com Phone(650) 624-1100Fax650-624-1101Employees174Year Founded1996Price Target and Rating Average Price Target for Rigel Pharmaceuticals$59.00 High Price Target$85.00 Low Price Target$38.00 Potential Upside/Downside+30.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$16.32 Trailing P/E Ratio2.78 Forward P/E Ratio15.22 P/E GrowthN/ANet Income$367.02 million Net Margins116.30% Pretax Margin30.92% Return on Equity22.95% Return on Assets17.19% Debt Debt-to-Equity RatioN/A Current Ratio1.94 Quick Ratio1.79 Sales & Book Value Annual Sales$276.79 million Price / Sales3.03 Cash Flow$6.47 per share Price / Cash Flow7.01 Book Value$21.57 per share Price / Book2.10Miscellaneous Outstanding Shares18,502,000Free Float16,565,000Market Cap$839.07 million OptionableOptionable Beta1.20 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RIGL) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
